Interested in stem cell developments.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This sounds good to me.
Ocata Therapeutics Secures $10 Million in Debt Financing
Business Wire Ocata Therapeutics, Inc.
MARLBOROUGH, Mass.--(BUSINESS WIRE)--
Ocata Therapeutics, Inc. (OCAT), a leader in the field of Regenerative Ophthalmology™, today announced that it has entered into a secured term loan facility of up to $10 million with Silicon Valley Bank. Ocata received initial funding of $6 million and has a conditional option to receive an additional $4 million upon the successful completion of certain clinical and corporate milestones. Ocata intends to use the proceeds for general corporate purposes including the initiation of the Phase 2 dry age-related macular degeneration (AMD) and pivotal Stargardt’s macular degeneration (SMD) clinical studies and the advancement of its promising pre-clinical programs.
“We are pleased to secure this additional, non-dilutive financing from a leading debt lender, with a history of supporting emerging biotechnology companies,” said Ted Myles, Chief Financial Officer and Chief Operating Officer. “The addition of this debt facility to the proceeds from our recently completed equity offering provides us with additional flexibility as we initiate our dry AMD Phase 2 safety trial, planned for this quarter and our SMD pivotal study, planned for the fourth quarter of this year.”
Katherine Andersen, Managing Director of Silicon Valley Bank commented, “We are pleased to partner with the Ocata Therapeutics team, which is driving important medical advancements to treat vision loss. Our aim is to provide Ocata with the right financing and global services as the company continues to advance its exciting programs.”
RE: <<ANY supposed "large buying" occurring has been off-set by much LARGER NET SELLING. It's just that simple. Stocks DO NOT decline 50% in a very short period because they're supposedly being "bought" in large quantities, LOL !!!
Nope, statistically impossible. The money-flow has been OUT of this stock- it's in a massive unbroken DOWN TREND and has been in a large net sell-off for months. Not the contrary supposed "large buying" occurring.>>
In all honesty, Captain, we do have to say that we don't yet know if the selling which you correctly observe is being done, as you imply, by the Institutions, maybe but maybe not.
Good post.
Many here are quite knowledgeable with respect to the stock market and make very knowledgeable observations about OCAT, the stock, of course given the pps action, generally negative. They do, however, seem to almost make it a point to stay away from discussing the incredible scientific achievements of Lanza and his team.
You've always been electric, north. ;)
As I already pointed out, RTM, I still do expect to make tons of money on my investment in Ocata.
It is annoying me, too, north. Some kind of computer glitch. Sorry about it, but it is not my doing.
I now notice it even happened to RTM.
Re: "If people really want to "feel good" then they should donate money to poor, homeless people. They should go buy canned food and feed the hungry."
I, for one, do some of that as well, RTM. That is, in part, why investing in Ocata is a very satisfying investment for me. It has the potential to make tons of money for me but if it fails the IRS division of my mind will allow me to write if off as a charitable donation. I do admit that, of course, I prefer the former with the much broader scope of good feeling.
Re: "Absolutely not. You don't come to Wall St. hoping to be a part of some great cause for humanity. .."
Speak for yourself, RTM. I am not saying that is the primary factor but it is a factor in the case of companies like Ocata, that can make for a very satisfying investment.
I would say there are many here and elsewhere who are invested in Ocata in part because they find the goals of Ocata to be compelling and admirable. I, myself, have found it easier to put more money into Ocata than otherwise. Of course, I do think Ocata will succeed in a major way. But even in the case that they do succeed in improving the quality of life of many but don't make money, there will still be considerable joy to be taken from that.
I even think it sad that there may also be many invested in Ocata solely to make money with no concern for or understanding of the goals towards which Ocata is striving.
As you know, fairview, or certainly should know, Lanza has an independently overseen automatic program in place (in part for tax paying purposes) and generally a very sound component of those automatic programs is to sell on spikes in the PPS.
Re: "Putting money in OCAT for anything but making money is nonsense."
Making money is certainly a prime factor but there is also the good feeling, if the venture is successful, of helping to greatly improve the quality of life of many blind and partially blind people and, once that is achieved, of helping to improve the quality of life for people with many other illnesses.
I bought more last week and today at $4.15.
Captain Kirk, what is your evaluation of the presentation by Dr. Lanza at the Common Good Forum on May 14, 2015. With respect to his observations on continuing success in the Ocata science do you see anything valid or promising therein or just more jiggery-pokery?
It is possible news is coming.
fulleroots, I think the current stock price is miserable.
Captain Kirk, what is your evaluation of the presentation by Dr. Lanza at the Common Good Forum on May 14, 2015. With respect to his observations on continuing success in the Ocata science do you see anything valid or promising therein or just more jiggery-pokery?
Captain Kirk, what is your opinion of Lanza’s observation that Ocata in their studies of animals with autoimmune diseases is having much greater success with their own ES-derived MSCs, as opposed to the more commonly used bone marrow derived MSCs, because of the much greater ability of the former to extravasate and thus more efficiently migrate to the damaged cells to achieve their healing effect?
Good points 2020.
Quote LOL, "OCAT is close to major success. "
NO, NO it actually is not "close" to anything at this point in time????
It's YEARS away (at best) from even knowing if they will have a FAILED PHASE II, IF they ever manage to even start the thing, now going on ONE YEAR LATE, LOL !!!
They're not "close" to anything- other than maybe running out of cash, LOL.
5 YEARS minimum and a massive amount of dilution and more insider self enrichment is about all that is "certain" with this lil ole micro-cap of big promises and lots of FAILURE TO EXECUTE AND DELIVER.
++++++++++++++++++++
Captain Kirk, it sounds like there was a comment during the recent ASM about possible SMD treatment approval in 2019. What is your evaluation of that?
Quote LOL, "OCAT is close to major success. "
NO, NO it actually is not "close" to anything at this point in time????
It's YEARS away (at best) from even knowing if they will have a FAILED PHASE II, IF they ever manage to even start the thing, now going on ONE YEAR LATE, LOL !!!
They're not "close" to anything- other than maybe running out of cash, LOL.
5 YEARS minimum and a massive amount of dilution and more insider self enrichment is about all that is "certain" with this lil ole micro-cap of big promises and lots of FAILURE TO EXECUTE AND DELIVER.
++++++++++++++++++++
Captain Kirk, it sounds like there was a comment during the recent ASM about possible SMD treatment approval in 2019. What is your evaluation of that?
Captain Kirk, it sounds like there was a comment during yesterday's ASM about possible SMD treatment approval in 2019. What is your evaluation of that?
Sounds good to me, chuckanutman.
Ocata Therapeutics Receives New U.S. Patent for Its RPE Therapy for Macular Degenerative Diseases
New Patent Strengthens Ocata’s Proprietary Position of its RPE Manufacturing Process from All Pluripotent Stem Cell Sources
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- 7/15/2015
Ocata Therapeutics, Inc. (OCAT), a leader in the field of Regenerative Ophthalmology™, today announced that it continues to fortify the patent protection covering its retinal pigment epithelium (RPE) transplant technology for macular degeneration with the issuance by the United States Patent and Trademark Office (USPTO) of U.S. Patent No 9,080,150.
“The issuance of this 9th U.S. patent in our global RPE portfolio represents yet another example of the leadership position we have established as pioneers in Regenerative Ophthalmology,” said Paul K. Wotton, Ph.D., President and Chief Executive Officer. “In particular, this new patent provides coverage for the manufacture of all RPE products from any pluripotent source by defining the basic universal markers of RPE essential for therapeutic use. We have recently received patent protection for the manufacture of human RPE cell products from pluripotent stem cell sources, including manufacture of formulation forms for use as therapeutic agents as well as the use of these RPE formulations for treating degenerative ophthalmic diseases, such as dry age-related macular degeneration (dry AMD) and Stargardt’s macular degeneration (SMD).”
Captain Kirk, this is a very long and very impressive response on this particular issue. Keep up the great work.
elysse, have you given consideration to the fact that currently Ocata has limited resources and their main function should be to keep their eye on the prize and make sure they (and we investors and future patients) get the benefits that will provide.
I consider my own emails or emails of others to them to not be that important in the grand scheme. For one thing, no one there could provide you or me or anyone else with information that hasn't been officially released. What info are you hoping to get from them that could appropriately be provided to you?
Captain Kirk, well stated, and because of all the very good points you made here I believe it is the case that The Lancet does not publish studies wherein the results are based on anecdote(s).
In fact, if you wanted to, you could easily look up the impressive variety of precise measurements used in the The Lancet study.
Re: " Sticking a huge needle in the eye is pretty stone aged sounding anyways"
Just for absolute basics, it is hardly a HUGE needle.
Re: " Sticking a huge needle in the eye is pretty stone aged sounding anyways"
As John McEnroe said "YOU CAN'T BE SERIOUS!!!!"
CAPTAIN KIRK, WHAT IS YOUR EVALUATION OF THE PRESENTATION BY DR. LANZA AT THE COMMON GOOD FORUM ON MAY 14, 2015, ANYTHING VALID OR PROMISING THEREIN OR JUST MORE JIGGERY-POKERY?
“$4.92, SOLID RED again and heading for a new 52 WEEK LOW.
NO, this is not supposed "big institutions" buying OCAT, LOL !!!
The stock is SELLING OFF as it has been for going on TWO MONTHS NOW.”
OCAT closes at $5.13 +0.04 with DOW -46, NASDAQ -17, S+P —8, LOL !!!
Sounds like the turnaround has started.
CAPTAIN KIRK, WHAT IS YOUR EVALUATION OF THE PRESENTATION BY DR. LANZA AT THE COMMON GOOD FORUM ON MAY 14, 2015, ANYTHING VALID OR PROMISING THEREIN OR JUST MORE JIGGERY-POKERY?
CAPTAIN KIRK, WHAT IS YOUR EVALUATION OF THE PRESENTATION BY DR. LANZA AT THE COMMON GOOD FORUM ON MAY 14, 2015, ANYTHING VALID OR PROMISING THEREIN OR JUST MORE JIGGERY-POKERY?
Captain Kirk, what is your evaluation of the presentation of Dr. Lanza at The Common Good Forum on May 14, 2015, anything valid or promising therein or just more jiggery-pokery?
Captain Kirk, what is your evaluation of the presentation of Dr. Lanza at The Common Good Forum on May 14, 2015, anything valid or promising therein or just more jiggery-pokery?
Great point, elysse. Because chuckanutman used a butterfly analogy we can soundly conclude that Ocata has about one month to go.
Captain Kirk, your analysis of "ringing the bell" is quite correct, if not a little like dropping an anvil on an ant. But do you really think Rabin will ring the bell?
elysse, since you’re talking boxing, keep in mind that many jeer at, boo and look down on Floyd Mayweather, one of the very best boxers in the history of the game, for questionable and immoral actions in the past and for being, in their minds, a boring fighter even if he does win over and over again.
"It will probably be delayed."
To Q3?